Should You Buy Alibaba Stock Despite the Risks?
Markets rebounded slightly after U.S. President Donald Trump announced a…
Sell
32
LCTX Quote, Financials, Valuation and Earnings
Last price:
$0.47
Seasonality move
:
-6.61%
Day range:
$0.42 - $0.47
52-week range:
$0.37 - $1.40
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
9.95x
P/B ratio:
1.38x
Volume:
1.2M
Avg. volume:
1.6M
1-year change:
-58.6%
Market cap:
$107.8M
Revenue:
$9.5M
EPS (TTM):
-$0.10
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
LCTX
Lineage Cell Therapeutics
|
$1.7M | -$0.03 | 22.46% | -6.67% | $3.92 |
|
AGEN
Agenus
|
$22M | -$1.66 | -5.82% | -97.37% | $6.00 |
|
CHRS
Coherus BioSciences
|
$53.7M | -$0.15 | -80.24% | -81.63% | $4.83 |
|
LFMD
LifeMD
|
$62.5M | $0.14 | 41.44% | -93.33% | $12.00 |
|
MYO
Myomo
|
$9.2M | -$0.08 | 145.61% | -24% | $9.25 |
|
VYGR
Voyager Therapeutics
|
$13.6M | -$0.44 | -30.56% | -119.44% | $16.10 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
LCTX
Lineage Cell Therapeutics
|
$0.47 | $3.92 | $107.8M | -- | $0.00 | 0% | 9.95x |
|
AGEN
Agenus
|
$2.85 | $6.00 | $72.1M | -- | $0.00 | 0% | 0.46x |
|
CHRS
Coherus BioSciences
|
$1.11 | $4.83 | $128.6M | 5.84x | $0.00 | 0% | 0.49x |
|
LFMD
LifeMD
|
$5.82 | $12.00 | $259.5M | -- | $0.00 | 0% | 1.13x |
|
MYO
Myomo
|
$4.65 | $9.25 | $159.9M | -- | $0.00 | 0% | 5.39x |
|
VYGR
Voyager Therapeutics
|
$3.49 | $16.10 | $192.7M | 6.11x | $0.00 | 0% | 2.52x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
LCTX
Lineage Cell Therapeutics
|
-- | 0.987 | -- | 3.47x |
|
AGEN
Agenus
|
-11.31% | 3.589 | 39.16% | 0.18x |
|
CHRS
Coherus BioSciences
|
199.29% | 3.337 | 166.05% | 0.88x |
|
LFMD
LifeMD
|
142.71% | 1.030 | 9.09% | 0.72x |
|
MYO
Myomo
|
-- | 2.090 | -- | 2.82x |
|
VYGR
Voyager Therapeutics
|
-- | 1.524 | -- | 5.45x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
LCTX
Lineage Cell Therapeutics
|
$2.7M | -$5.1M | -27.23% | -27.23% | -178.17% | -$6.7M |
|
AGEN
Agenus
|
-$7.1M | -$28M | -- | -- | -97.33% | -$28.7M |
|
CHRS
Coherus BioSciences
|
$20.3M | -$42.2M | 12.26% | -- | -83.76% | $28.6M |
|
LFMD
LifeMD
|
$54.8M | $1M | -109.9% | -- | 1.59% | -$1.2M |
|
MYO
Myomo
|
$8.6M | -$245.3K | -48.64% | -48.64% | -2.03% | $2.5M |
|
VYGR
Voyager Therapeutics
|
-- | -$38.3M | -21.07% | -21.07% | -610.05% | -$14.7M |
Lineage Cell Therapeutics vs. Competitors
-
Which has Higher Returns LCTX or AGEN?
Agenus has a net margin of -114.12% compared to Lineage Cell Therapeutics's net margin of -170.88%. Lineage Cell Therapeutics's return on equity of -27.23% beat Agenus's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital LCTXLineage Cell Therapeutics94.63% -$0.01 $77M AGENAgenus-26.29% -$1.94 -$273.3M -
What do Analysts Say About LCTX or AGEN?
Lineage Cell Therapeutics has a consensus price target of $3.92, signalling upside risk potential of 729.8%. On the other hand Agenus has an analysts' consensus of $6.00 which suggests that it could grow by 110.53%. Given that Lineage Cell Therapeutics has higher upside potential than Agenus, analysts believe Lineage Cell Therapeutics is more attractive than Agenus.
Company Buy Ratings Hold Ratings Sell Ratings LCTXLineage Cell Therapeutics4 1 0 AGENAgenus1 4 0 -
Is LCTX or AGEN More Risky?
Lineage Cell Therapeutics has a beta of 1.323, which suggesting that the stock is 32.28% more volatile than S&P 500. In comparison Agenus has a beta of 1.578, suggesting its more volatile than the S&P 500 by 57.761%.
-
Which is a Better Dividend Stock LCTX or AGEN?
Lineage Cell Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Agenus offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Lineage Cell Therapeutics pays -- of its earnings as a dividend. Agenus pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios LCTX or AGEN?
Lineage Cell Therapeutics quarterly revenues are $2.9M, which are smaller than Agenus quarterly revenues of $26.8M. Lineage Cell Therapeutics's net income of -$3.3M is higher than Agenus's net income of -$45.9M. Notably, Lineage Cell Therapeutics's price-to-earnings ratio is -- while Agenus's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Lineage Cell Therapeutics is 9.95x versus 0.46x for Agenus. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income LCTXLineage Cell Therapeutics9.95x -- $2.9M -$3.3M AGENAgenus0.46x -- $26.8M -$45.9M
-
Which has Higher Returns LCTX or CHRS?
Coherus BioSciences has a net margin of -114.12% compared to Lineage Cell Therapeutics's net margin of -93.63%. Lineage Cell Therapeutics's return on equity of -27.23% beat Coherus BioSciences's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital LCTXLineage Cell Therapeutics94.63% -$0.01 $77M CHRSCoherus BioSciences37.47% -$0.44 $132.9M -
What do Analysts Say About LCTX or CHRS?
Lineage Cell Therapeutics has a consensus price target of $3.92, signalling upside risk potential of 729.8%. On the other hand Coherus BioSciences has an analysts' consensus of $4.83 which suggests that it could grow by 335.44%. Given that Lineage Cell Therapeutics has higher upside potential than Coherus BioSciences, analysts believe Lineage Cell Therapeutics is more attractive than Coherus BioSciences.
Company Buy Ratings Hold Ratings Sell Ratings LCTXLineage Cell Therapeutics4 1 0 CHRSCoherus BioSciences3 1 0 -
Is LCTX or CHRS More Risky?
Lineage Cell Therapeutics has a beta of 1.323, which suggesting that the stock is 32.28% more volatile than S&P 500. In comparison Coherus BioSciences has a beta of 1.009, suggesting its more volatile than the S&P 500 by 0.891%.
-
Which is a Better Dividend Stock LCTX or CHRS?
Lineage Cell Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Coherus BioSciences offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Lineage Cell Therapeutics pays -- of its earnings as a dividend. Coherus BioSciences pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios LCTX or CHRS?
Lineage Cell Therapeutics quarterly revenues are $2.9M, which are smaller than Coherus BioSciences quarterly revenues of $54.1M. Lineage Cell Therapeutics's net income of -$3.3M is higher than Coherus BioSciences's net income of -$50.7M. Notably, Lineage Cell Therapeutics's price-to-earnings ratio is -- while Coherus BioSciences's PE ratio is 5.84x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Lineage Cell Therapeutics is 9.95x versus 0.49x for Coherus BioSciences. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income LCTXLineage Cell Therapeutics9.95x -- $2.9M -$3.3M CHRSCoherus BioSciences0.49x 5.84x $54.1M -$50.7M
-
Which has Higher Returns LCTX or LFMD?
LifeMD has a net margin of -114.12% compared to Lineage Cell Therapeutics's net margin of -0.17%. Lineage Cell Therapeutics's return on equity of -27.23% beat LifeMD's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital LCTXLineage Cell Therapeutics94.63% -$0.01 $77M LFMDLifeMD85.32% -$0.02 $14.3M -
What do Analysts Say About LCTX or LFMD?
Lineage Cell Therapeutics has a consensus price target of $3.92, signalling upside risk potential of 729.8%. On the other hand LifeMD has an analysts' consensus of $12.00 which suggests that it could grow by 106.19%. Given that Lineage Cell Therapeutics has higher upside potential than LifeMD, analysts believe Lineage Cell Therapeutics is more attractive than LifeMD.
Company Buy Ratings Hold Ratings Sell Ratings LCTXLineage Cell Therapeutics4 1 0 LFMDLifeMD7 1 0 -
Is LCTX or LFMD More Risky?
Lineage Cell Therapeutics has a beta of 1.323, which suggesting that the stock is 32.28% more volatile than S&P 500. In comparison LifeMD has a beta of 2.221, suggesting its more volatile than the S&P 500 by 122.141%.
-
Which is a Better Dividend Stock LCTX or LFMD?
Lineage Cell Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. LifeMD offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Lineage Cell Therapeutics pays -- of its earnings as a dividend. LifeMD pays out -16.45% of its earnings as a dividend.
-
Which has Better Financial Ratios LCTX or LFMD?
Lineage Cell Therapeutics quarterly revenues are $2.9M, which are smaller than LifeMD quarterly revenues of $64.3M. Lineage Cell Therapeutics's net income of -$3.3M is lower than LifeMD's net income of -$106.3K. Notably, Lineage Cell Therapeutics's price-to-earnings ratio is -- while LifeMD's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Lineage Cell Therapeutics is 9.95x versus 1.13x for LifeMD. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income LCTXLineage Cell Therapeutics9.95x -- $2.9M -$3.3M LFMDLifeMD1.13x -- $64.3M -$106.3K
-
Which has Higher Returns LCTX or MYO?
Myomo has a net margin of -114.12% compared to Lineage Cell Therapeutics's net margin of -2.16%. Lineage Cell Therapeutics's return on equity of -27.23% beat Myomo's return on equity of -48.64%.
Company Gross Margin Earnings Per Share Invested Capital LCTXLineage Cell Therapeutics94.63% -$0.01 $77M MYOMyomo71.39% -$0.01 $24.7M -
What do Analysts Say About LCTX or MYO?
Lineage Cell Therapeutics has a consensus price target of $3.92, signalling upside risk potential of 729.8%. On the other hand Myomo has an analysts' consensus of $9.25 which suggests that it could grow by 98.93%. Given that Lineage Cell Therapeutics has higher upside potential than Myomo, analysts believe Lineage Cell Therapeutics is more attractive than Myomo.
Company Buy Ratings Hold Ratings Sell Ratings LCTXLineage Cell Therapeutics4 1 0 MYOMyomo3 0 0 -
Is LCTX or MYO More Risky?
Lineage Cell Therapeutics has a beta of 1.323, which suggesting that the stock is 32.28% more volatile than S&P 500. In comparison Myomo has a beta of 1.548, suggesting its more volatile than the S&P 500 by 54.752%.
-
Which is a Better Dividend Stock LCTX or MYO?
Lineage Cell Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Myomo offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Lineage Cell Therapeutics pays -- of its earnings as a dividend. Myomo pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios LCTX or MYO?
Lineage Cell Therapeutics quarterly revenues are $2.9M, which are smaller than Myomo quarterly revenues of $12.1M. Lineage Cell Therapeutics's net income of -$3.3M is lower than Myomo's net income of -$260.1K. Notably, Lineage Cell Therapeutics's price-to-earnings ratio is -- while Myomo's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Lineage Cell Therapeutics is 9.95x versus 5.39x for Myomo. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income LCTXLineage Cell Therapeutics9.95x -- $2.9M -$3.3M MYOMyomo5.39x -- $12.1M -$260.1K
-
Which has Higher Returns LCTX or VYGR?
Voyager Therapeutics has a net margin of -114.12% compared to Lineage Cell Therapeutics's net margin of -549.33%. Lineage Cell Therapeutics's return on equity of -27.23% beat Voyager Therapeutics's return on equity of -21.07%.
Company Gross Margin Earnings Per Share Invested Capital LCTXLineage Cell Therapeutics94.63% -$0.01 $77M VYGRVoyager Therapeutics-- -$0.59 $299.8M -
What do Analysts Say About LCTX or VYGR?
Lineage Cell Therapeutics has a consensus price target of $3.92, signalling upside risk potential of 729.8%. On the other hand Voyager Therapeutics has an analysts' consensus of $16.10 which suggests that it could grow by 361.32%. Given that Lineage Cell Therapeutics has higher upside potential than Voyager Therapeutics, analysts believe Lineage Cell Therapeutics is more attractive than Voyager Therapeutics.
Company Buy Ratings Hold Ratings Sell Ratings LCTXLineage Cell Therapeutics4 1 0 VYGRVoyager Therapeutics11 0 0 -
Is LCTX or VYGR More Risky?
Lineage Cell Therapeutics has a beta of 1.323, which suggesting that the stock is 32.28% more volatile than S&P 500. In comparison Voyager Therapeutics has a beta of 1.018, suggesting its more volatile than the S&P 500 by 1.773%.
-
Which is a Better Dividend Stock LCTX or VYGR?
Lineage Cell Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Voyager Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Lineage Cell Therapeutics pays -- of its earnings as a dividend. Voyager Therapeutics pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios LCTX or VYGR?
Lineage Cell Therapeutics quarterly revenues are $2.9M, which are smaller than Voyager Therapeutics quarterly revenues of $6.3M. Lineage Cell Therapeutics's net income of -$3.3M is higher than Voyager Therapeutics's net income of -$34.5M. Notably, Lineage Cell Therapeutics's price-to-earnings ratio is -- while Voyager Therapeutics's PE ratio is 6.11x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Lineage Cell Therapeutics is 9.95x versus 2.52x for Voyager Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income LCTXLineage Cell Therapeutics9.95x -- $2.9M -$3.3M VYGRVoyager Therapeutics2.52x 6.11x $6.3M -$34.5M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Is Intel Struggling Against AMD?
Due to its disappointing reports, so-so management, and lack of…
Will PayPal Stock Recover or Keep Sliding?
Payments platform behemoth PayPal Holdings, Inc. (NASDAQ:PYPL) is going through…
Stock Ideas
Buy
56
Is AAPL Stock a Buy?
Market Cap: $3.1T
P/E Ratio: 34x
Buy
51
Is MSFT Stock a Buy?
Market Cap: $2.8T
P/E Ratio: 32x
Sell
49
Is NVDA Stock a Buy?
Market Cap: $2.5T
P/E Ratio: 35x
Alerts
Buy
71
PEGA alert for Apr 24
Pegasystems [PEGA] is up 2.36% over the past day.
Buy
67
SMMT alert for Apr 24
Summit Therapeutics [SMMT] is up 4.63% over the past day.
Sell
36
ENPH alert for Apr 24
Enphase Energy [ENPH] is up 2.13% over the past day.
